The custom manufacturing and technology business of Royal DSM, DSM pharmaceuticals has inked a deal with a privately held biopharma firms that formulates fresh and precisely aimed protein Tunitas Therapeutics of San Francisco.
The deal incorporates, initiation of process growing activities by DSM for Tunitas' lead Fc-fusion protein for the treatment of asthma and other allergic diseases.
"We are delighted to be working with DSM Biologics for the production of Tunitas' first clinical candidate." said Nolan Sigal, president and CEO of Tunitas Therapeutics. "DSM has an outstanding and well-earned reputation for the production of biologics of the highest quality. Furthermore, the opening of the DSM's state-of-the-art facility in Brisbane, Australia fits nicely with our strategy to begin development activities in Australia."
Manja Bouman, president of DSM Biologics, commented: "It is an honour to support the development of Tunitas' promising drug candidate from our facilities in Groningen and Australia. We are impressed with the potential of this product and the health benefit to treat the millions of patients whose asthma is poorly-controlled on their current therapeutic regimens."
Further, in accession to an R&D and manufacturing site in Groningen, The Netherlands, DSM has started functioning in Brisbane, Australia, with the support of the Governments of Queensland and the Commonwealth.
The deal incorporates, initiation of process growing activities by DSM for Tunitas' lead Fc-fusion protein for the treatment of asthma and other allergic diseases.
"We are delighted to be working with DSM Biologics for the production of Tunitas' first clinical candidate." said Nolan Sigal, president and CEO of Tunitas Therapeutics. "DSM has an outstanding and well-earned reputation for the production of biologics of the highest quality. Furthermore, the opening of the DSM's state-of-the-art facility in Brisbane, Australia fits nicely with our strategy to begin development activities in Australia."
Manja Bouman, president of DSM Biologics, commented: "It is an honour to support the development of Tunitas' promising drug candidate from our facilities in Groningen and Australia. We are impressed with the potential of this product and the health benefit to treat the millions of patients whose asthma is poorly-controlled on their current therapeutic regimens."
Further, in accession to an R&D and manufacturing site in Groningen, The Netherlands, DSM has started functioning in Brisbane, Australia, with the support of the Governments of Queensland and the Commonwealth.